Mandate

Vinge advises CELLINK in connection with listing on Nasdaq First North

October 07, 2016

Vinge has advised CELLINK AB (publ) in connection with its listing on Nasdaq First North.

The information memorandum was published on 7 October 2016 and the estimated first day of trading is 3 November 2016. The subscription price in the offer is SEK 26 per share, which corresponds to a pre-money value for CELLINK of approximately MSEK 156. No shares or other securities are being sold by existing shareholders in connection with the offer.

CELLINK develops and sells bioink and bioprinters. Bioink can be combined with conductive cells in order to print functional living tissue and, if future research is successful, complete human organs. CELLINK was founded in 2016 and has won several awards, both scientific and business related, for successful entrepreneurship.

 Vinge’s team consisted of responsible partner Anders Strid together with Frida Bäckegren (capital markets), Jonas Lindblad (employment), Joel Zetterström and Natalie Bäck (IT), Karin Wisenius (competition), Victor Ericsson (tax) and corporate assistant Camilla Andersson.    

Related

Vinge advises Baseload Capital in connection with an investment from Google

Vinge has advised Baseload Capital Holding AB in connection with securing an investment from Google.
April 16, 2025

Vinge advises Acrinova in connection with the sale of properties

Vinge advises Acrinova AB (publ) in connection with its sale of properties with an underlying property value of SEK 1.4 billion.
April 15, 2025

Vinge has advised Visa in connection with its investment in Mynt AB

Vinge has advised Visa in connection with its investment in the Swedish fintech company Mynt AB ("Mynt"). The investment, which is part of Mynt's announced Series B funding round, underscores Visa's commitment to supporting innovative fintech solutions and improving payment experiences for businesses across Europe.
April 14, 2025